DOAC-Stop is intended to be used with plasma samples containing DOACs. Follow procedures and refer to precautions that may affect the stated

INDEMNITY NOTICE
For research use only in USA and Australia/NZ. DOAC-Stop may extract low molecular weight compounds resembling DOACs from plasmas. Plasmas treated with DOAC-Stop may be used for reliable routine assessment of known blood coagulation parameters. The degree of shortening

APPLICATION
Plasmas treated with DOAC-Stop may be used for reliable routine assessment of known blood coagulation parameters. The degree of shortening

LIMITATIONS
For research use only in USA and Australia/NZ. DOAC-Stop may extract low molecular weight compounds resembling DOACs from plasmas. Those affecting coagulation (but administered intravenously, not orally) include argatroban, aprotinin, protamine, hirudin analogues, polymyxin and related cationic compounds.

PERFORMANCE CHARACTERISTICS
One mini-tab of DOAC Stop in 1.0mL of normal plasma spiked with 500ng/ml of dabigatran, apixaban, rivaroxaban or edoxaban will remove more than 95% of the DOAC. There was no effect on the baseline APTT’s after 3 hours further incubation. In 92 test plasma samples covering a range of abnormalities, 89 gave definitive results and 3 were equivocal after DOAC-Stop in view of sample complexity [1].

A recent study on 135 DOAC-treated plasmas showed that DOAC Stop was mostly effective in overcoming the effects of dabigatran in 40 cases, apixaban in 38 cases, rivaroxaban 42 cases and edoxaban 15 cases on several thrombophilia screening tests. The incidence of false positive lupus anticoagulants fell from approximately 30% to zero [2].

INDEMNITY NOTICE
DOAC-Stop is intended to be used with plasma samples containing DOACs. Follow procedures and refer to precautions that may affect the stated or implied claims and performance of this product. Cellabs, Haematex and its agents or distributors are not liable for damages. Note that the vial contains an adherent desiccant capsule. Do not disturb.

REFERENCES